Last reviewed · How we verify
Perfluorobutane (PERFLUBUTANE)
Perfluorobutane (generic name: PERFLUBUTANE) is a perflubutane drug. It is currently in Phase 3 development.
Perflubutane works by dissolving in the bloodstream and accumulating in the lungs, allowing for imaging and diagnosis of lung conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PERFLUBUTANE |
|---|---|
| Drug class | perflubutane |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Imagine a special gas that can be breathed in and then seen on a scan. This gas, perflubutane, is used to help doctors see inside the lungs and diagnose problems. It's like a temporary, invisible dye that helps doctors get a clearer picture of what's going on inside the body.
Approved indications
Common side effects
Key clinical trials
- Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (PHASE1,PHASE2)
- Y-90 Treatment Response Using Transarterial Radioembolization (PHASE2)
- Gynecological Sentinel Lymph Nodes CEUS (EARLY_PHASE1)
- Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer (EARLY_PHASE1)
- SHAPE of Portal Hypertension in Children (PHASE2)
- Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection (PHASE2)
- Contrast Ultrasound Detection of Sentinel Lymph Nodes (PHASE1,PHASE2)
- Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perfluorobutane CI brief — competitive landscape report
- Perfluorobutane updates RSS · CI watch RSS
Frequently asked questions about Perfluorobutane
What is Perfluorobutane?
How does Perfluorobutane work?
What is the generic name of Perfluorobutane?
What drug class is Perfluorobutane in?
What development phase is Perfluorobutane in?
Related
- Drug class: All perflubutane drugs
- Therapeutic area: All drugs in Respiratory
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing